Johnson & Johnson's Janssen Says Subcutaneous Rybrevant Approved for 2 Indications in EU

MT Newswires Live04-07

Johnson & Johnson's (JNJ) Janssen-Cilag International said Monday it received European Commission approval for its subcutaneous formulation of Rybrevant, or amivantamab, in two indications.

The subcutaneous formulation was approved in combination with lazertinib as the first-line treatment for advanced EGFR-mutated non-small cell lung cancer, and as a monotherapy for patients with EGFR exon 20 insertion mutations after platinum-based therapy failure, the company said.

The company said subcutaneous amivantamab was formulated using Halozyme Therapeutics' (HALO) drug delivery technology.

Johnson & Johnson said the approval follows positive results from a phase 3 study, which achieved its primary endpoints and indicated that subcutaneous amivantamab was "non-inferior" to the intravenous formulation in terms of efficacy and pharmacokinetics.

Johnson & Johnson shares were down nearly 3% in recent Monday trading, while Halozyme stock was up more than 2%.

Price: 148.75, Change: -4.50, Percent Change: -2.93

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment